Infect Chemother.  2011 Feb;43(1):42-47. 10.3947/ic.2011.43.1.42.

What Strategy Can be Applied to the Patients with Culture Positive Tuberculosis to Reduce Treatment Delay in a Private Tertiary Healthcare Center?

• Lee JE
• Kim YK
• Kim TH
• Kim KH
• Lee EJ
• Uh ST
• Choi TY

• KMID: 2170332
• DOI: http://doi.org/10.3947/ic.2011.43.1.42

Abstract

BACKGROUND
The contribution of the private sector to the treatment of tuberculosis (TB) is getting larger, and the private sector pays more attention to individualized, intensive care than patient monitoring or education, which would improve the microbiological cure rate or at least completion of treatment. We aim in this paper to assess the impact of the improved monitoring of patient on the treatment outcome in the private tertiary healthcare center.
MATERIALS AND METHODS
We compared the data of the positive sputum cultures for TB from March 1, 2003 to March 31, 2006 (37 months) with that data from July 1, 2007 to August 31, 2008 (14 months) in single private tertiary healthcare center in the Republic of Korea (ROK). In the latter period, we notified physicians of the new culture-confirmed cases via a cellular phone short-massage-service (SMS) to prevent delayed recognition of positive cultures and we gave calls to patients to encourage treatment adherence and to complete the whole schedule of medication.
RESULTS
After the intervention, initiation of anti-TB medication increased from 86.3% to 94.5% (P<0.05), the interval to medication from the first culture results was shortened from 22.9 days to 5.6 days (P=0.19) and the rate of treatment complication increased from 57.4% to 68.1% (P<0.01).
CONCLUSION
Our results showed a possible strategy to improve the completion of treatment in a university hospital. Health care providers in the private sector should to improve success by better notification and monitoring in addition to their existing advanced medical resources.

Keyword

Mycobacterium tuberculosis; Nontuberculous mycobacteria; Public-Private partnership

MeSH Terms

Appointments and Schedules
Cellular Phone
Critical Care
Health Personnel
Humans
Monitoring, Physiologic
Mycobacterium tuberculosis
Nontuberculous Mycobacteria
Private Sector
Public-Private Sector Partnerships
Republic of Korea
Sputum
Tertiary Healthcare
Treatment Outcome
Tuberculosis

Reference

1. Ministry of Health and Welfare. Korean National Tuberculosis Association. Report on the 7th tuberculosis prevalence survey in Korea. 1995.

2. Korean Center for Disease Control and Prevention. 2007 Annual report on the notified tuberculosis patients in Korea. 2008. Seoul: KCDC.

3. Korea Centers for Disease Control and Prevention. 2009 Annual report on the notified tuberculosis patients in Korea. 2010.

4. Global Tuberculosis Control, 2010. World Health Organisation. Accessed 2 February 2011. Available at: http://www.who.int/tb/country/en/.

5. Joh JS, Lee CH, Lee JE, Park YK, Bai GH, Kim EC, Han SK, Shim YS, Yim JJ. The Interval between initiation of anti-tuberculosis treatment in patients with culture-positive pulmonary tuberculosis and receipt of drug-susceptibility test results. J Korean Med Sci. 2007. 22:26–29.

6. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis. 2001. 5:1129–1136.

7. Choi JC, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, Lee NY, Park YK, Bai GH, Koh WJ. Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea. J Korean Med Sci. 2007. 22:677–681.

8. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007. 11:571–576.

9. Koh WJ, Kwon OJ, Yu CM, Jeon KM, Suh GY, Chung MP, Kim HJ, Han SW, Park SY, Lee NY. Recovery rate of Nontuberculous Mycobacteria from acid-fast-bacilli smear-positive sputum specimens. Tuberc Respir Dis. 2003. 54:22–32.

10. Lee JY, Choi HJ, Lee H, Joung EY, Huh JW, Oh YM, Lee SD, Kim WS, Kim DS, Kim WD, Shim TS. Recovery rate and characteristics of Nontuberculous Mycobacterial isolates in a university hospital in Korea. Tuberc Respir Dis. 2005. 58:385–391.

11. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med. 2002. 23:553–567.

12. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, Bai GH. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest. 2006. 129:341–348.

13. Koh WJ, Kwon OJ, Lee KS. Diagnosis and treatment of nontuberculous mycobacterial pulmonary diseases: A Korean perspective. J Korean Med Sci. 2005. 20:913–925.

14. Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis. 2003. 7:912–919.

15. Ambe G, Lönnroth K, Dholakia Y, Copreaux J, Zignol M, Borremans N, Uplekar M. Every provider counts: effect of a comprehensive public-private mix approach for TB control in a large metropolitan area in India. Int J Tuberc Lung Dis. 2005. 9:562–568.